A college research foundation licensed the use of its proprietary protein growth technology to a major US biotechnology company. The foundation suspected that the company was underpaying its royalty obligations, and retained CRA to perform a royalty audit. CRA consultants with expertise in microbiology interviewed the licensee’s technical personnel, revealing that numerous products, which were being produced using the licensed process, had been excluded from royalty calculations. The licensee had previously denied that these products were produced using the licensed technology. Additionally, it was discovered that the licensee had failed to pay royalties on various products produced for “research” purposes.
Patent Damages: Recent Trends in Daubert Decisions
In this Insights, we update the Daubert Decision trends in last year’s Insights with 2021 data.[1] Daubert Decision trends are based on our review of available...